Arlene Chan, Marc Buyse, Bin Yao  The Lancet Oncology 

Slides:



Advertisements
Similar presentations
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials The Lancet Volume 386, Issue.
Advertisements

Crohn's disease Prof Daniel C Baumgart, MD, Prof William J Sandborn, MD The Lancet Volume 380, Issue 9853, Pages (November 2012) DOI: /S (12)
Chee-Seng Tan, MRCP, David Gilligan, FRCPE, Dr Simon Pacey, FRCP 
Volume 349, Issue 9057, Pages (April 1997)
Food systems, nutrition, health and the environment
Intention-to-treat population
Activity of trastuzumab-emtansine (TDM1) in HER2-positive breast cancer brain metastases: A case series  Kevin C. Keith, Yueh Lee, Matthew G. Ewend, Timothy.
Volume 64, Pages e1-e3 (January 2017)
Thank God for Richard Dawkins?
Long-term effects of hormone replacement therapy
The benefits and harms of breast cancer screening
The commercial determinants of health
Volume 13, Issue 12, Pages (December 2012)
Volume 9, Issue 12, Pages (December 2008)
Long-term effects of hormone replacement therapy
Gareth L Ackland, Maurizio Cecconi, Rupert M Pearse 
Underestimate of annual malaria imports to Canada – Author reply
Political factors behind US global AIDS programmes slow-down
Charity begins at home in global health research funding
Klebsiella pneumoniae liver abscesses
Threats to human health by great ocean garbage patches
Pain in cancer survivors; filling in the gaps
Aspirin in the prevention of cancer – Author's reply
Do air quality alerts benefit public health? New evidence from Canada
Genetics of lung cancer susceptibility and COPD
Volume 10, Issue 6, Pages (June 2009)
Gene therapy in haematology and oncology
T-DM1-related carotenoderma and hand-foot syndrome
Gene therapy—where are we?
Volume 12, Issue 12, Pages (November 2011)
Burden of obstetric fistula: from measurement to action
Effective cross-sector collaborations create sustainability
Adjuvant chemotherapy for rectal cancer – Authors' reply
Breastfeeding in the 21st century
Incident diabetes in clinical trials of antihypertensive drugs
Ovarian cancer screening: UKCTOCS trial – Authors' reply
Arnaud Chiolero  The Lancet Public Health 
Jonathan Broad, Matthew D Snape  The Lancet Public Health 
HIV myths should not be resuscitated
Overcoming resistance of cancer stem cells
Effect of development assistance on domestic health expenditures
Food systems, nutrition, health and the environment
Psychological response and survival in breast cancer
Volume 13, Issue 12, Pages (December 2012)
Sherif M Abdalla, Robert Bortolussi, Noni E MacDonald 
Adrian Martineau  The Lancet Respiratory Medicine 
Jeffrey Bradley, MD, Issam El Naqa, PhD  Journal of Thoracic Oncology 
Confessions of a journal junkie
Telling it like it isn't: truth and lies in a post-9/11 world
Volume 9, Issue 4, Pages (April 2008)
Volume 377, Issue 9771, Pages (March 2011)
Thank God for Richard Dawkins?
Erratum Journal of Thoracic Oncology
Low-technology approaches
Thank you to our diverse (but not diverse enough) reviewers
Vitamin D status and ill health – Author's reply
Matthieu J Guitton  The Lancet Planetary Health 
Costs of eliminating HIV in South Africa have been underestimated
Steven A Narod  The Lancet  Volume 349, Issue 9068, (June 1997)
Spatial lifecourse epidemiology
Genetic enhancement of radionuclide cancer therapy
Political factors behind US global AIDS programmes slow-down
Maximizing Disease-Free Survival in Early-Stage HER2-Positive Breast Cancer.
Refining treatment choices for ADHD
Pleurodesis for primary spontaneous pneumothorax – Authors' reply
Institutional challenges to achieving health equity in Ecuador
Symptom-based stratification of autoimmune diseases
Sickle cell disease: a new era
Volume 374, Issue 9694, Pages (September 2009)
A disease of the osteoblast
Presentation transcript:

Neratinib after trastuzumab in patients with HER2-positive breast cancer – Author's reply  Arlene Chan, Marc Buyse, Bin Yao  The Lancet Oncology  Volume 17, Issue 5, Pages e176-e177 (May 2016) DOI: 10.1016/S1470-2045(16)30018-3 Copyright © 2016 Elsevier Ltd Terms and Conditions

Figure Disease-free survival in patients 24 months after treatment with neratinib or placebo after trastuzumab-based adjuvant therapy The Lancet Oncology 2016 17, e176-e177DOI: (10.1016/S1470-2045(16)30018-3) Copyright © 2016 Elsevier Ltd Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.